ylliX - Online Advertising Network
Company Ticker News

Bristol Myers Touts 5-Year Kidney Cancer Data For Opdivo-Yervoy Combo Therapy

Bristol Myers Touts 5-Year Kidney Cancer Data For Opdivo-Yervoy Combo Therapy

<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>

Bristol Myers Squibb Co (NYSE: BMY) announced Opdivo (nivolumab) plus Yervoy (ipilimumab) long-term survival data in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC). Data were presented at the European Society for Medical Oncology Virtual Congress 2021 (ESMO21).

...read full article on Benzinga

ylliX - Online Advertising Network